Biogen (BIIB) Gains from Investment Securities (2016 - 2025)
Historic Gains from Investment Securities for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to -$19.0 million.
- Biogen's Gains from Investment Securities rose 7054.26% to -$19.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$41.1 million, marking a year-over-year decrease of 76290.32%. This contributed to the annual value of -$68.3 million for FY2025, which is 5720.55% up from last year.
- Latest data reveals that Biogen reported Gains from Investment Securities of -$19.0 million as of Q4 2025, which was up 7054.26% from $5.6 million recorded in Q3 2025.
- In the past 5 years, Biogen's Gains from Investment Securities registered a high of $503.7 million during Q3 2022, and its lowest value of -$437.6 million during Q1 2021.
- In the last 5 years, Biogen's Gains from Investment Securities had a median value of -$1.4 million in 2023 and averaged $411764.7.
- Its Gains from Investment Securities has fluctuated over the past 5 years, first soared by 80967.74% in 2021, then crashed by 450714.29% in 2024.
- Quarter analysis of 5 years shows Biogen's Gains from Investment Securities stood at -$116.3 million in 2021, then skyrocketed by 331.56% to $269.3 million in 2022, then crashed by 100.52% to -$1.4 million in 2023, then crashed by 4507.14% to -$64.5 million in 2024, then skyrocketed by 70.54% to -$19.0 million in 2025.
- Its Gains from Investment Securities was -$19.0 million in Q4 2025, compared to $5.6 million in Q3 2025 and $13.2 million in Q2 2025.